Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jun
26
Today In Oncology
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
Multi-Cancer Early Detection Test Performs Well in Real-World Asian Cohort
Subgroup Analysis Demonstrates Efficacy of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo